Identification

Name
Apixaban
Accession Number
DB06605  (DB07828)
Type
Small Molecule
Groups
Approved
Description

Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor (of both free and prothrombinase-bound FXa independently of antithrombin III) for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. FDA approved on December 28, 2012.

Structure
Thumb
Synonyms
  • apixabán
  • apixabanum
External IDs
BMS 562247-01 / BMS-562247 / BMS-562247-01
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet2.5 mgOralBristol Myers Squibb2012-02-01Not applicableCanada
EliquisTablet, film coated2.5 mg/1OralE.R. Squibb & Sons, L.L.C.2012-12-28Not applicableUs00003 0893 21 nlmimage10 4048a055
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet, film coated5 mg/1OralA S Medication Solutions2012-12-282017-06-20Us
EliquisTablet, film coated2.5 mgOralBristol Myers Squibb / Pfizer Eeig2011-05-18Not applicableEu
EliquisTablet5.0 mgOralBristol Myers Squibb2012-12-21Not applicableCanada
Categories
UNII
3Z9Y7UWC1J
CAS number
503612-47-3
Weight
Average: 459.4971
Monoisotopic: 459.190654313
Chemical Formula
C25H25N5O4
InChI Key
QNZCBYKSOIHPEH-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
IUPAC Name
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide
SMILES
COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O

Pharmacology

Indication

Apixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.

Structured Indications
Pharmacodynamics

Apixaban acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban. The Rotachrom® Heparin chromogenic assay is not recommended for assessing the anticoagulant effect of apixaban.

Mechanism of action

Apixaban acts by directly inhibiting, in a reversible manner, free and clot-bound factor Xa to inhibit coagulation.

TargetActionsOrganism
ACoagulation factor X
inhibitor
Human
Absorption

Apixaban is absorbed in the stomach and small intestine. For doses up to 10 mg, the absolute bioavailability is about 50%. For oral administration, absorption is not affected by the presence of food, and it takes about 3-4 hours to achieve maximum plasma concentrations. For large oral doses equal or greater than 25 mg, absorption is dissolution limited and bioavailability is decreased. Most of the absorption occurs in the distal small intestine and the ascending colon.

Volume of distribution

The steady state volume of distribution is 21 L.

Protein binding

Apixaban is about 87% plasma protein bound.

Metabolism

Apixaban mainly undergoes o-demethylation and hydroxylation to metabolites. The major site of biotransformation is at the 3-oxopiperidinyl moiety. The main enzyme responsible for metabolism is CYP3A4/5 while CYP1A2, 2C8, 2C9, 2C19, and 2J2 are minor metabolic enzymes. There are no active metabolites and unchanged apixaban is the primary circulating entity.

Route of elimination

25% of the administered dose is eliminated in the feces and urine. For elimination in the feces, it is excreted by the intestine and bile to the feces.

Half life

If administered orally, the half life is 12 hours (due to prolonged absorption). If administerd by I.V., the half-life is about 5 hours.

Clearance

About 27% of total apixaban is renally cleared.

Toxicity

Major bleeding events.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Apixaban.Approved, Investigational
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Apixaban.Approved
AbirateroneThe serum concentration of Apixaban can be increased when it is combined with Abiraterone.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Apixaban.Approved, Investigational
AcemetacinAcemetacin may increase the anticoagulant activities of Apixaban.Approved
AcenocoumarolApixaban may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Apixaban.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Apixaban.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Apixaban.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Apixaban.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Apixaban.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Apixaban.Approved, Illicit, Investigational
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Apixaban.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Apixaban.Approved
AltrenogestThe therapeutic efficacy of Apixaban can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Apixaban.Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Apixaban.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Apixaban.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Apixaban.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Apixaban.Approved
AmiodaroneThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Apixaban.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Apixaban.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Apixaban.Approved
AncrodApixaban may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Apixaban.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Apixaban.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Apixaban.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Apixaban.Approved
Antithrombin III humanApixaban may increase the anticoagulant activities of Antithrombin III human.Approved
ApocyninApocynin may increase the anticoagulant activities of Apixaban.Investigational
ApremilastApremilast may increase the anticoagulant activities of Apixaban.Approved, Investigational
AprepitantThe serum concentration of Apixaban can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Apixaban can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinApixaban may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Apixaban.Approved, Investigational
ArmodafinilThe metabolism of Apixaban can be decreased when combined with Armodafinil.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Apixaban.Investigational
AtazanavirThe serum concentration of Apixaban can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Apixaban can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Apixaban.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Apixaban.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Apixaban.Approved
AzithromycinThe metabolism of Apixaban can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Apixaban.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Apixaban.Experimental
BecaplerminApixaban may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Apixaban.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Apixaban.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Apixaban.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Apixaban.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Apixaban.Approved
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Apixaban.Investigational
BevoniumBevonium may increase the anticoagulant activities of Apixaban.Experimental
BivalirudinApixaban may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Apixaban can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Apixaban can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Apixaban can be decreased when it is combined with Bosentan.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Apixaban.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Apixaban.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Apixaban.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Apixaban.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Apixaban.Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Apixaban.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Apixaban.Experimental
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Apixaban.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Apixaban.Approved
CaffeineThe metabolism of Apixaban can be decreased when combined with Caffeine.Approved
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Apixaban.Approved
CapecitabineThe metabolism of Apixaban can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Apixaban can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Apixaban.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Apixaban.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Apixaban.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Apixaban.Approved, Investigational
CeritinibThe serum concentration of Apixaban can be increased when it is combined with Ceritinib.Approved
CertoparinApixaban may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloramphenicolThe metabolism of Apixaban can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineChloroquine may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Apixaban.Investigational, Withdrawn
CholecalciferolThe metabolism of Apixaban can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Apixaban.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Apixaban.Approved
CimetidineThe metabolism of Apixaban can be decreased when combined with Cimetidine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Apixaban.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Apixaban can be decreased when combined with Citalopram.Approved
Citric AcidApixaban may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Apixaban.Approved
ClemastineThe serum concentration of Apixaban can be increased when it is combined with Clemastine.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Apixaban.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Apixaban.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Apixaban.Approved, Nutraceutical
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Apixaban.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Apixaban.Experimental
ClotrimazoleThe serum concentration of Apixaban can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Apixaban can be increased when it is combined with Cobicistat.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Apixaban is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Apixaban can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Apixaban.Approved
CrisaboroleThe metabolism of Apixaban can be decreased when combined with Crisaborole.Approved
CrizotinibThe serum concentration of Apixaban can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Apixaban.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Apixaban is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Apixaban.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Apixaban can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Apixaban.Investigational
Dabigatran etexilateApixaban may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Apixaban can be decreased when it is combined with Dabrafenib.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Apixaban.Experimental
DalteparinApixaban may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidApixaban may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanApixaban may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe serum concentration of Apixaban can be increased when it is combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Apixaban.Approved, Investigational
DeferasiroxThe serum concentration of Apixaban can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Apixaban.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Apixaban.Approved
DemegestoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Apixaban is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Apixaban.Investigational
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Apixaban.Approved
DesirudinApixaban may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Apixaban.Investigational
DesogestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Desogestrel.Approved
DextranApixaban may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Apixaban may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Apixaban may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Apixaban may increase the anticoagulant activities of Dextran 75.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Apixaban.Experimental
DiclofenacDiclofenac may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
DicoumarolApixaban may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Apixaban.Approved, Investigational
DienogestThe therapeutic efficacy of Apixaban can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Apixaban.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Apixaban.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Apixaban.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Apixaban.Approved
DihydroergotamineThe serum concentration of Apixaban can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Apixaban can be increased when it is combined with Diltiazem.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Apixaban.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Apixaban.Approved
DitazoleDitazole may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
DosulepinThe metabolism of Apixaban can be decreased when combined with Dosulepin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Apixaban.Approved
DoxycyclineThe serum concentration of Apixaban can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Apixaban can be increased when it is combined with Dronedarone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Apixaban.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Apixaban.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Apixaban.Investigational
DydrogesteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Apixaban.Approved
E-6201E-6201 may increase the anticoagulant activities of Apixaban.Investigational
Edetic AcidApixaban may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanApixaban may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Apixaban can be decreased when combined with Efavirenz.Approved, Investigational
EltrombopagThe serum concentration of Apixaban can be increased when it is combined with Eltrombopag.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Apixaban.Approved, Investigational
EnoxaparinApixaban may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Apixaban can be decreased when it is combined with Enzalutamide.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Apixaban.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Apixaban.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Apixaban.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Apixaban.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Apixaban.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Apixaban.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Apixaban.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Apixaban.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Apixaban.Approved
ErythromycinThe serum concentration of Apixaban can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Apixaban can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Apixaban.Investigational
EsomeprazoleThe metabolism of Apixaban can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Apixaban.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Apixaban.Approved
EstriolEstriol may decrease the anticoagulant activities of Apixaban.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Apixaban.Approved
EstroneEstrone may decrease the anticoagulant activities of Apixaban.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Apixaban.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Apixaban.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Apixaban.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Apixaban.Approved
Ethyl biscoumacetateApixaban may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthynodiolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Ethynodiol.Experimental
EtodolacEtodolac may increase the anticoagulant activities of Apixaban.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Apixaban.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Apixaban.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Apixaban.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Apixaban.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Apixaban.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Apixaban.Experimental
FelodipineThe metabolism of Apixaban can be decreased when combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Apixaban.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Apixaban.Approved
FentiazacFentiazac may increase the anticoagulant activities of Apixaban.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Apixaban.Experimental
Ferulic acidApixaban may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Apixaban.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
FloxuridineThe metabolism of Apixaban can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Apixaban can be increased when it is combined with Fluconazole.Approved
FluindioneApixaban may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Apixaban.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Apixaban.Experimental
FluorouracilThe metabolism of Apixaban can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Apixaban can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Apixaban.Approved, Investigational
FluvastatinThe metabolism of Apixaban can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Apixaban can be increased when it is combined with Fluvoxamine.Approved, Investigational
FondaparinuxApixaban may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumApixaban may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosamprenavirThe serum concentration of Apixaban can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Apixaban can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Apixaban can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Apixaban can be increased when it is combined with Fusidic Acid.Approved
GabexateApixaban may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Apixaban can be decreased when it is combined with Garlic.Approved
GemfibrozilThe metabolism of Apixaban can be decreased when combined with Gemfibrozil.Approved
GenisteinGenistein may decrease the anticoagulant activities of Apixaban.Investigational
GestodeneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Apixaban.Experimental
HeminHemin may increase the anticoagulant activities of Apixaban.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Apixaban.Experimental
HeparinApixaban may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Apixaban.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Apixaban.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Apixaban.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Apixaban.Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Apixaban.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Apixaban.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Apixaban.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Apixaban.Approved
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Apixaban.Approved, Nutraceutical
IdelalisibThe serum concentration of Apixaban can be increased when it is combined with Idelalisib.Approved
IdraparinuxApixaban may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Apixaban.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Apixaban.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Apixaban.Approved, Investigational
ImatinibThe serum concentration of Apixaban can be increased when it is combined with Imatinib.Approved
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Apixaban.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Apixaban.Approved
IndinavirThe serum concentration of Apixaban can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Apixaban.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Apixaban.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Apixaban.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Apixaban.Experimental
IrbesartanThe metabolism of Apixaban can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Apixaban can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Apixaban can be decreased when combined with Isoniazid.Approved
IsoxicamIsoxicam may increase the anticoagulant activities of Apixaban.Withdrawn
IsradipineThe serum concentration of Apixaban can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Apixaban can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Apixaban can be increased when it is combined with Ivacaftor.Approved
KebuzoneKebuzone may increase the anticoagulant activities of Apixaban.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Apixaban.Investigational
KetoconazoleThe serum concentration of Apixaban can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Apixaban.Approved
LapatinibThe metabolism of Apixaban can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Apixaban can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinApixaban may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanApixaban may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Apixaban can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LidocaineThe metabolism of Apixaban can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Apixaban.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Apixaban.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Apixaban.Investigational
LobeglitazoneThe metabolism of Apixaban can be decreased when combined with Lobeglitazone.Approved, Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Apixaban.Experimental
LonazolacLonazolac may increase the anticoagulant activities of Apixaban.Experimental
LopinavirThe serum concentration of Apixaban can be increased when it is combined with Lopinavir.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Apixaban.Approved, Investigational
LosartanThe metabolism of Apixaban can be decreased when combined with Losartan.Approved
LovastatinThe serum concentration of Apixaban can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Apixaban.Approved, Investigational
LuliconazoleThe serum concentration of Apixaban can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Apixaban can be increased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Apixaban.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Apixaban.Approved
ManidipineThe metabolism of Apixaban can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolMasoprocol may increase the anticoagulant activities of Apixaban.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Apixaban.Approved
Megestrol acetateThe therapeutic efficacy of Apixaban can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MelagatranApixaban may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Apixaban.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Apixaban.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Apixaban.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Apixaban.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Apixaban.Approved
MethylestrenoloneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Methylestrenolone.Experimental
MexiletineThe metabolism of Apixaban can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Apixaban.Approved, Illicit
MidostaurinThe metabolism of Apixaban can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Apixaban can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Apixaban.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Apixaban.Approved
MitotaneThe serum concentration of Apixaban can be decreased when it is combined with Mitotane.Approved
MizoribineMizoribine may increase the anticoagulant activities of Apixaban.Investigational
MoclobemideThe metabolism of Apixaban can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Apixaban can be decreased when combined with Modafinil.Approved, Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Apixaban.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Apixaban.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Apixaban.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Apixaban.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Apixaban.Approved
NadroparinApixaban may increase the anticoagulant activities of Nadroparin.Approved
NafamostatApixaban may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Apixaban.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Apixaban.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Apixaban.Approved, Vet Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Apixaban.Approved, Withdrawn
NelfinavirThe serum concentration of Apixaban can be increased when it is combined with Nelfinavir.Approved
NepafenacNepafenac may increase the anticoagulant activities of Apixaban.Approved
NetupitantThe serum concentration of Apixaban can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Apixaban can be increased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Apixaban can be decreased when combined with Nicardipine.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Apixaban.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Apixaban.Approved
NilotinibThe serum concentration of Apixaban can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apixaban.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Apixaban is combined with Nintedanib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Apixaban.Investigational
NomegestrolThe therapeutic efficacy of Apixaban can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Apixaban.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Apixaban is combined with Obinutuzumab.Approved
OlaparibThe serum concentration of Apixaban can be increased when it is combined with Olaparib.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Apixaban.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Apixaban.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Apixaban is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Apixaban.Approved, Nutraceutical
OmeprazoleThe metabolism of Apixaban can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Apixaban.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Apixaban.Vet Approved
OsimertinibThe serum concentration of Apixaban can be increased when it is combined with Osimertinib.Approved
OtamixabanApixaban may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Apixaban.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Apixaban.Investigational
PalbociclibThe serum concentration of Apixaban can be increased when it is combined with Palbociclib.Approved
PantoprazoleThe metabolism of Apixaban can be decreased when combined with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Apixaban.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Apixaban.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Apixaban.Investigational
Peginterferon alfa-2bThe serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.Approved
Pentaerythritol TetranitrateApixaban may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe serum concentration of Apixaban can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Apixaban.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Apixaban.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Apixaban is combined with Pethidine.Approved
PhenindioneApixaban may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Apixaban can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonApixaban may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
PhenytoinThe serum concentration of Apixaban can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Apixaban.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Apixaban.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Apixaban.Approved
PioglitazoneThe metabolism of Apixaban can be decreased when combined with Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Apixaban.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Apixaban.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Apixaban.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Apixaban.Approved
PosaconazoleThe serum concentration of Apixaban can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Apixaban.Experimental, Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Apixaban.Approved
PrimidoneThe serum concentration of Apixaban can be decreased when it is combined with Primidone.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Apixaban.Experimental
PromegestoneThe therapeutic efficacy of Apixaban can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Apixaban.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Apixaban.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Apixaban.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Apixaban.Experimental
Protein CApixaban may increase the anticoagulant activities of Protein C.Approved
Protein S humanApixaban may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeApixaban may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Apixaban.Approved
PTC299PTC299 may increase the anticoagulant activities of Apixaban.Investigational
PyrimethamineThe metabolism of Apixaban can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinestrolQuinestrol may decrease the anticoagulant activities of Apixaban.Approved
QuinineThe metabolism of Apixaban can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Apixaban can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Apixaban.Investigational
RanolazineThe serum concentration of Apixaban can be increased when it is combined with Ranolazine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Apixaban.Approved
ReviparinApixaban may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Apixaban.Approved
RifabutinThe serum concentration of Apixaban can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Apixaban can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Apixaban can be decreased when it is combined with Rifapentine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Apixaban.Approved
RivaroxabanApixaban may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Apixaban.Investigational, Withdrawn
RolapitantThe serum concentration of Apixaban can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Apixaban can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Apixaban.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Apixaban.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Apixaban.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Apixaban.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Apixaban.Approved
SaquinavirThe serum concentration of Apixaban can be increased when it is combined with Saquinavir.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Apixaban.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Apixaban.Experimental
SecobarbitalThe metabolism of Apixaban can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Apixaban.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Apixaban.Approved
SemapimodSemapimod may increase the anticoagulant activities of Apixaban.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Apixaban.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Apixaban.Investigational
SertralineThe metabolism of Apixaban can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Apixaban.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Apixaban.Approved, Investigational
SiltuximabThe serum concentration of Apixaban can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Apixaban can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Apixaban.Approved
SorafenibThe metabolism of Apixaban can be decreased when combined with Sorafenib.Approved, Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Apixaban.Investigational
St. John's WortThe serum concentration of Apixaban can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Apixaban can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the anticoagulant activities of Apixaban.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Apixaban.Approved
SulfadiazineThe metabolism of Apixaban can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Apixaban can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Apixaban.Approved
SulfisoxazoleThe serum concentration of Apixaban can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the anticoagulant activities of Apixaban.Approved
SulodexideApixaban may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Apixaban.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Apixaban.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Apixaban.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Apixaban.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Apixaban.Approved, Investigational
TamoxifenThe metabolism of Apixaban can be decreased when combined with Tamoxifen.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Apixaban.Investigational
TelaprevirThe serum concentration of Apixaban can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Apixaban can be increased when it is combined with Telithromycin.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Apixaban is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Apixaban.Approved
TenidapTenidap may increase the anticoagulant activities of Apixaban.Experimental
Tenofovir disoproxilThe metabolism of Apixaban can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may increase the anticoagulant activities of Apixaban.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Apixaban.Vet Approved
TeriflunomideThe serum concentration of Apixaban can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Apixaban.Investigational
TheophyllineThe metabolism of Apixaban can be decreased when combined with Theophylline.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Apixaban.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Apixaban.Approved
TiboloneTibolone may increase the anticoagulant activities of Apixaban.Approved, Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Apixaban.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Apixaban.Approved
TinoridineTinoridine may increase the anticoagulant activities of Apixaban.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Apixaban.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Apixaban.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Apixaban.Approved, Investigational
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Apixaban.Approved
TocilizumabThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Apixaban can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Apixaban.Approved
TolmetinTolmetin may increase the anticoagulant activities of Apixaban.Approved
TopiramateThe metabolism of Apixaban can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Apixaban can be decreased when combined with Topiroxostat.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Apixaban is combined with Tositumomab.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Apixaban.Approved, Investigational
TranylcypromineThe metabolism of Apixaban can be decreased when combined with Tranylcypromine.Approved
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Apixaban.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Apixaban.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Apixaban.Approved
TribenosideTribenoside may increase the anticoagulant activities of Apixaban.Experimental
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Apixaban.Approved, Investigational
TrimethoprimThe metabolism of Apixaban can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Apixaban.Approved
TriptolideTriptolide may increase the anticoagulant activities of Apixaban.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Apixaban.Approved
TroxerutinApixaban may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Apixaban.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Apixaban.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Apixaban.Approved, Investigational
ValsartanThe metabolism of Apixaban can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Apixaban can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Apixaban can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Apixaban can be increased when it is combined with Verapamil.Approved
Vitamin EVitamin E may increase the anticoagulant activities of Apixaban.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Apixaban.Approved
VoriconazoleThe serum concentration of Apixaban can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinApixaban may increase the anticoagulant activities of Warfarin.Approved
XimelagatranApixaban may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Apixaban can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Apixaban.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Apixaban.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Apixaban.Approved
ZileutonZileuton may increase the anticoagulant activities of Apixaban.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Apixaban can be increased when it is combined with Ziprasidone.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Apixaban.Withdrawn
ZucapsaicinThe metabolism of Apixaban can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Alfalfa, Anise, Bilberry may increase the adverse effects of apixaban.
  • Grapefruit juice may increase apixaban serum concentration.
  • St. John's wort will likely decrease apixaban serum concentration. Avoid combination if possible.

References

General References
  1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. [PubMed:21870978]
  2. de Souza Brito F, Lopes RD, Alexander JH: The safety and efficacy of apixaban : where do we stand in 2013? Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. [PubMed:23662974]
External Links
KEGG Drug
D03213
PubChem Compound
10182969
PubChem Substance
175427077
ChemSpider
8358471
BindingDB
19023
ChEBI
72296
ChEMBL
CHEMBL231779
PharmGKB
PA166163740
HET
GG2
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Apixaban
ATC Codes
B01AF02 — Apixaban
AHFS Codes
  • 20:12.04.14 — Direct Factor Xa Inhibitors
PDB Entries
2p16
FDA label
Download (655 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableEnd Stage Renal Disease (ESRD)1
1CompletedNot AvailableThrombosis1
1CompletedBasic ScienceAnticoagulation1
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics / Venous Thromboembolism1
1CompletedBasic ScienceN/A - Healthy Subjects2
1CompletedBasic ScienceThrombosis1
1CompletedBasic ScienceVenous Thromboembolism1
1CompletedTreatmentAcute Coronary Syndromes (ACS) / Nonvalvular Atrial Fibrillation1
1CompletedTreatmentHaemorrhage1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentThrombosis1
1RecruitingOtherThromboembolism1
1RecruitingTreatmentCombination of Oral Anticoagulation Therapy and Sildenafil / Intermediate-high Risk / Prophylaxis of Pulmonary embolism1
1TerminatedOtherVenous Thromboembolism1
1, 2RecruitingOtherGlomerulonephritis minimal lesion / Proteinuria1
2CompletedPreventionAcute Coronary Syndromes (ACS)1
2CompletedPreventionCancers / Prophylaxis of Pulmonary embolism / Thrombosis1
2CompletedTreatmentDeep-Vein Thrombosis1
2CompletedTreatmentNonvalvular Atrial Fibrillation1
2Not Yet RecruitingPreventionVTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery1
2RecruitingPreventionAnti-Xa Activity1
2RecruitingPreventionCancers / Venous Thromboembolism1
2RecruitingPreventionGynecologic Cancers / Venous Thromboembolism1
2RecruitingPreventionKnee Arthroplasty, Total1
2RecruitingTreatmentHaemorrhage1
2RecruitingTreatmentIntracerebral Hemorrhage / Nonvalvular Atrial Fibrillation1
2RecruitingTreatmentThrombosis1
2TerminatedTreatmentAcute Coronary Syndromes (ACS)1
2WithdrawnNot AvailableNonvalvular Atrial Fibrillation1
2WithdrawnPreventionCardiac Implantable Electronic Device / Patent Foramen Ovale (PFO)1
2, 3CompletedPreventionProphylaxis of Pulmonary embolism / Thrombosis, Venous1
2, 3RecruitingPreventionCoronary Artery Bypass Grafting (CABG) Surgery / Deep Venous Thrombosis / Postoperative Atrial Fibrilation / Strokes / Systemic Embolism1
2, 3RecruitingTreatmentMenstruation / Venous Thromboembolism1
2, 3Unknown StatusTreatmentStroke, Ischemic / Transient Ischaemic Attack (TIA)1
3Active Not RecruitingPreventionReduction in Hospitalizations / Sickle Cell Disorders / Vaso-Occlusive Crises1
3Active Not RecruitingSupportive CareCerebral Vein Thrombosis / Deep Vein Thrombosis (DVT) / Gonadal Thrombosis / Hepatic Thrombosis / Mesenteric Thrombosis / Metastatic Malignant Neoplasm / Neoplasms, Malignant / Portal Vein Thrombosis / Prophylaxis of Pulmonary embolism / Renal Vein Thrombosis / Splenic thrombosis / Venous Thromboembolism1
3CompletedPreventionAtrial Flutter / Nonvalvular Atrial Fibrillation1
3CompletedPreventionDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism2
3CompletedPreventionNonvalvular Atrial Fibrillation1
3CompletedPreventionProphylaxis of Pulmonary embolism / Thrombosis, Venous1
3CompletedTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism2
3CompletedTreatmentThrombosis, Venous2
3Not Yet RecruitingPreventionAtrial Flutter / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Nonvalvular Atrial Fibrillation / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma1
3Not Yet RecruitingTreatmentAcute Myocardial Infarction (AMI) / Anticoagulants and Bleeding Disorders / Left Ventricular Thrombosis1
3Not Yet RecruitingTreatmentEnd-Stage Kidney Disease / Nonvalvular Atrial Fibrillation1
3Not Yet RecruitingTreatmentVenous Thromboembolism1
3RecruitingPreventionAcute Lymphoblastic Leukaemias (ALL) / Malignant Lymphomas1
3RecruitingPreventionDeep Vein Thrombosis (DVT) / Metastatic Malignant Neoplasm / Neoplasms, Malignant / Prophylaxis of Pulmonary embolism1
3RecruitingPreventionNonvalvular Atrial Fibrillation / Strokes / Transient Ischaemic Attack (TIA)1
3RecruitingTreatmentEligible for Transcatheter Aortic Valve Replacement / Symptomatic Aortic Stenosis1
3RecruitingTreatmentEmbolic Stroke1
3RecruitingTreatmentHematoma1
3RecruitingTreatmentImpaired Renal Function1
3RecruitingTreatmentLeft Ventricular Thrombosis1
3RecruitingTreatmentPlasma Cell Myeloma / Venous Thromboembolism1
3RecruitingTreatmentVenous Thromboembolism1
3TerminatedPreventionAcute Coronary Syndromes (ACS)1
4Active Not RecruitingTreatmentNonvalvular Atrial Fibrillation1
4Active Not RecruitingTreatmentVenous Thromboembolism1
4CompletedNot AvailableEnd-Stage Renal Disease (ESRD) / ESRD1
4CompletedNot AvailableNon-valvular Atrial Fibrillation (NVAF)1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedSupportive CareNonvalvular Atrial Fibrillation1
4CompletedTreatmentNonvalvular Atrial Fibrillation1
4Not Yet RecruitingBasic ScienceBMI >30 kg/m2 / Post-gastrointestinal bypass surgery1
4Not Yet RecruitingPreventionMultiple Myeloma (MM) / Venous Thromboembolism1
4Not Yet RecruitingTreatmentVenous Thromboembolism1
4RecruitingOtherAcute Coronary Syndromes (ACS)1
4RecruitingPreventionAntiphospholipid Syndrome / Thrombosis1
4RecruitingPreventionNonvalvular Atrial Fibrillation1
4RecruitingPreventionNonvalvular Atrial Fibrillation / Strokes1
4RecruitingPreventionVentricular Tachycardia (VT)1
4RecruitingTreatmentAnticoagulation1
4RecruitingTreatmentDeep Vein Thrombosis (DVT) / Deep Venous Thrombosis / Thromboembolism / Upper Extremity Deep Venous Thrombosis / Venous Thromboembolism1
4RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
4RecruitingTreatmentDiabetes1
4RecruitingTreatmentEnd Stage Renal Disease (ESRD) / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentNeoplasms / Thrombosis, Venous1
4RecruitingTreatmentNonvalvular Atrial Fibrillation1
4RecruitingTreatmentVenous Thromboembolism1
Not AvailableActive Not RecruitingNot AvailableAnticoagulation1
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation2
Not AvailableActive Not RecruitingNot AvailableStroke, Ischemic1
Not AvailableActive Not RecruitingNot AvailableStrokes1
Not AvailableAvailableNot AvailableThromboembolism1
Not AvailableCompletedNot AvailableAnticoagulation1
Not AvailableCompletedNot AvailableDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
Not AvailableCompletedNot AvailableMajor Bleeding / Venous Thromboembolism1
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation5
Not AvailableCompletedNot AvailableVenous Thromboembolism1
Not AvailableNot Yet RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableNot Yet RecruitingNot AvailableStroke, Ischemic1
Not AvailableRecruitingNot AvailableAnticoagulants and Bleeding Disorders / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableCancer Patients / Central Venous Catheter Thrombosis / Upper Extremity Thrombosis1
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableRecruitingNot AvailableVenous Thromboembolism1
Not AvailableRecruitingScreeningCoagulation Disorders / Non Valvular Atrial Fibrillation1
Not AvailableRecruitingSupportive CareHemorrhage / Nonvalvular Atrial Fibrillation / Periodontal Diseases1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
Not AvailableRecruitingTreatmentPersistent Atrial Fibrillation1
Not AvailableWithdrawnNot AvailableNon-valvular Atrial Fibrillation (NVAF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral2.5 mg
TabletOral5.0 mg
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral2.5 mg
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral5 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2349330No2009-09-292019-12-17Canada
CA2461202No2011-07-122022-09-17Canada
US6413980No1999-12-222019-12-22Us
US6967208No2003-02-032023-02-03Us
US9326945No2011-02-242031-02-24Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityAqueous solubility: 40-50 μg/ml in 0.9% saline solutionNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0679 mg/mLALOGPS
logP2.22ALOGPS
logP1.83ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)13.12ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.76 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity126.9 m3·mol-1ChemAxon
Polarizability49.62 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9329
Caco-2 permeable-0.5308
P-glycoprotein substrateSubstrate0.6144
P-glycoprotein inhibitor IInhibitor0.6804
P-glycoprotein inhibitor IIInhibitor0.594
Renal organic cation transporterNon-inhibitor0.5628
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.811
CYP450 3A4 substrateSubstrate0.764
CYP450 1A2 substrateNon-inhibitor0.9271
CYP450 2C9 inhibitorInhibitor0.5555
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorInhibitor0.5
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6447
Ames testNon AMES toxic0.5062
CarcinogenicityNon-carcinogens0.8796
BiodegradationNot ready biodegradable0.9965
Rat acute toxicity2.3038 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8351
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0210900000-941cd1e773f20ff3a0d7

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Phenylpyrazoles / Pyridinecarboxamides / Methoxyanilines / 2-heteroaryl carboxamides / Pyrazole-5-carboxamides / Anisoles / Phenoxy compounds / Methoxybenzenes / Alkyl aryl ethers / Delta lactams
show 10 more
Substituents
Phenylpiperidine / Phenylpyrazole / Methoxyaniline / Pyridinecarboxamide / 2-heteroaryl carboxamide / Phenoxy compound / Anisole / Pyrazole-5-carboxamide / Phenol ether / Methoxybenzene
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, lactam, piperidones, pyrazolopyridine (CHEBI:72296)

Targets

Details
1. Coagulation factor X
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Spyropoulos AC: Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007 Apr;16(4):431-40. [PubMed:17371192]
  2. Harenberg J, Wehling M: Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023. [PubMed:18393142]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, Maxwell BD, Chen SY, He K, Goosen TC, Humphreys WG, Grossman SJ: In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58. doi: 10.1124/dmd.109.029694. Epub 2009 Nov 25. [PubMed:19940026]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible f...
Gene Name
CYP2J2
Uniprot ID
P51589
Uniprot Name
Cytochrome P450 2J2
Molecular Weight
57610.165 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. de Souza Brito F, Lopes RD, Alexander JH: The safety and efficacy of apixaban : where do we stand in 2013? Expert Opin Drug Saf. 2013 Jul;12(4):559-67. doi: 10.1517/14740338.2013.799663. Epub 2013 May 10. [PubMed:23662974]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da

Drug created on March 19, 2008 10:40 / Updated on November 19, 2017 20:33